Results 11 to 20 of about 50,080 (291)

Misoprostol for medical treatment of missed abortion: a systematic review and network meta-analysis

Scientific Reports, 2017
The efficacy and safety of misoprostol alone for missed abortion varied with different regimens. To evaluate existing evidence for the medical management of missed abortion using misoprostol, we undertook a comprehensive review and meta-analysis.
Hang-lin Wu, Sheeba Marwah, Pei Wang, Qiu-meng Wang, Xiao-wen Chen   +4 more
doaj   +2 more sources

Safety and effectiveness of self-managed abortion using misoprostol alone acquired from an online telemedicine service in the United States.

Perspectives on sexual and reproductive health, 2023
OBJECTIVES To evaluate self-reported outcomes and serious adverse events following self-managed medication abortion using misoprostol alone provided from an online service.
Dana M. Johnson, Mira Michels-Gualtieri, R. Gomperts, A. Aiken   +3 more
semanticscholar   +1 more source

Low-dose oral misoprostol for induction of labour.

Cochrane Database of Systematic Reviews, 2021
BACKGROUND Misoprostol given orally is a commonly used labour induction method. Our Cochrane Review is restricted to studies with low-dose misoprostol (initially ≤ 50 µg), as higher doses pose unacceptably high risks of uterine hyperstimulation ...
R. Kerr, Nimisha Kumar, Myfanwy J Williams, Anna Cuthbert, Nasreen B Aflaifel, D. Haas, A. Weeks   +6 more
semanticscholar   +1 more source

Pretreatment With Mifepristone Compared With Misoprostol Alone for Delivery After Fetal Death Between 14 and 28 Weeks of Gestation

Obstetrics and Gynecology, 2021
The sequential use of mifepristone and misoprostol for termination of pregnancy after fetal death between 14 and 28 weeks of gestation reduces time to delivery compared with misoprostol alone.
E. Allanson, Sean Copson, K. Spilsbury, Sonya Criddle, B. Jennings, D. Doherty, Antonia M. Wong, J. Dickinson   +7 more
semanticscholar   +1 more source

A Stalled Revolution? Misoprostol and the Pharmaceuticalization of Reproductive Health in Francophone Africa

Frontiers in Sociology, 2021
Misoprostol entered the global market under the name Cytotec in the mid-1980s for the treatment of gastric ulcers. Decades of research have since demonstrated the safety and effectiveness of off-label use of misoprostol as a uterotonic in pregnant women ...
S. Suh
semanticscholar   +1 more source

Cost‐effectiveness of mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage: an economic evaluation based on the MifeMiso trial

BJOG: an International Journal of Obstetrics and Gynaecology, 2021
To assess the cost‐effectiveness of mifepristone and misoprostol (MifeMiso) compared with misoprostol only for the medical management of a missed miscarriage.
C. Okeke Ogwulu, EV Williams, JJ Chu, A. Devall, Leanne Beeson, P. Hardy, V. Cheed, S. Yongzhong, LL Jones, JH La Fontaine Papadopoulos, R. Bender-Atik, J. Brewin, K. Hinshaw, M. Choudhary, A. Ahmed, J. Naftalin, N. Nunes, A. Oliver, F. Izzat, K. Bhatia, I. Hassan, Y. Jeve, J. Hamilton, S. Debs, C. Bottomley, J. Ross, L. Watkins, M. Underwood, Y. Cheong, Cs Kumar, P. Gupta, R. Small, S. Pringle, F. Hodge, A. Shahid, A. Horne, S. Quenby, I. Gallos, A. Coomarasamy, T. Roberts   +39 more
semanticscholar   +1 more source

Women’s self-reported experiences using misoprostol obtained from drug sellers: a prospective cohort study in Lagos State, Nigeria

BMJ Open, 2020
Objectives This study aimed to assess the safety and effectiveness of self-managed misoprostol abortions obtained outside of the formal health system in Lagos State, Nigeria.
Melissa Stillman, O. Owolabi, A. Fatusi, A. Akinyemi, A. Berry, T. Erinfolami, O. Olagunju, Heini Väisänen, A. Bankole   +8 more
semanticscholar   +1 more source

Oral misoprostol, low dose vaginal misoprostol, and vaginal dinoprostone for labor induction: Randomized controlled trial

PLoS ONE, 2020
Objective To compare effectiveness and safety of oral misoprostol (50 μg every four hours as needed), low dose vaginal misoprostol (25 to 50 μg every six hours as needed), and our established dinoprostone vaginal gel (one to two mg every six hours as ...
D. Young, D. Young, Tina Delaney, Tina Delaney, Tina Delaney, B. Armson, B. Armson, Cora A. Fanning, Cora A. Fanning   +8 more
semanticscholar   +1 more source

Intracervical Foley Catheter Plus Intravaginal Misoprostol vs Intravaginal Misoprostol Alone for Cervical Ripening: A Meta-Analysis

International Journal of Environmental Research and Public Health, 2020
Currently, there is no meta-analysis comparing intravaginal misoprostol plus intracervical Foley catheter versus intravaginal misoprostol alone for term pregnancy without identifying risk factors.
Howard Hao Lee, Ben Huang, Min Cheng, C. Yeh, I-Chia Lin, H. Horng, Hsin-Yi Huang, Wen-Ling Lee, Peng-Hui Wang   +8 more
semanticscholar   +1 more source

Quality, availability and storage conditions of oxytocin and misoprostol in Malawi

BMC Pregnancy and Childbirth, 2020
Background Postpartum haemorrhage (PPH) is the leading cause of maternal mortality in low- and middle-income countries (LMICs). Oxytocin and misoprostol are used for the prevention and treatment of PPH. However, both medicines are chemically unstable and
Nhomsai Hagen, Felix Khuluza, L. Heide
semanticscholar   +1 more source